Conference Coverage: ASCO 2025 – Focus on Lung Cancer
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment
Faculty Chair
Corey J. Langer, MD, FACP
University of Pennsylvania, Philadelphia, PA, USA
FACULTY MEMBERS
Marina Chiara Garassino, MD
University of Chicago, IL, USA
Nasser Hanna, MD
Indiana University School of Medicine, Indianapolis, IN, USA
Ignacio Wistuba, MD
MD Anderson Cancer Center, Houston, TX, USA
Charles Rudin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA
Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, USA
Solange Peters, MD, PhD
University of Lausanne, Switzerland
Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- What’s New in EGFR: Osimertinib and Beyond
- Targeting KRAS: G12C and Other Subtypes
- New Agents Targeting MET and HER2
- Immunotherapy in Resectable Stage I–III NSCLC: Updated Survival/Biomarker Analyses and New Agents
- Immunotherapy in Advanced/Metastatic NSCLC: Can We Improve on Anti–PD-(L)1?
- Broadening Approaches for Small Cell Lung Cancer
